What Dosage of Ozempic is Used for Weight Loss?

Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that has shown remarkable efficacy for weight reduction in clinical trials. When used specifically for weight management, semaglutide follows a carefully structured dosing schedule that begins low and increases incrementally over several months. Understanding how this dose progression works—and why it matters for your results—helps you prepare for your personalized treatment journey.

How Semaglutide Starting Doses Work for Weight Loss

The standard starting dose of semaglutide for weight loss is 0.25 mg injected subcutaneously once per week. This initial dose is intentionally low to allow your body to adapt to the medication and minimize side effects like nausea or appetite changes. Your healthcare provider will monitor your response during this first month before advancing to the next dose tier.

Week 5 through 8 typically introduces a 0.5 mg weekly dose, doubling the initial amount. Many people experience meaningful appetite reduction and early weight loss at this stage. The gradual escalation strategy helps distinguish between expected appetite suppression and adverse reactions that might require dose adjustment or medication switching.

By weeks 9-12, most treatment protocols move to 1.0 mg weekly, which is often considered the therapeutic dose for many patients. At this level, the medication's full GLP-1 receptor activation becomes evident through sustained satiety, reduced food cravings, and improved portion control. Some individuals achieve their weight loss goals at this dose and remain stable for months.

Standard Maintenance Doses and the 16-Week Titration Protocol

The final maintenance dose for semaglutide weight loss treatment is typically 2.4 mg weekly, reached around week 16-20 of therapy. Weeks 13-16 usually involve 1.7 mg weekly, the penultimate step before reaching the maximum recommended dose. This prolonged titration schedule—rather than jumping directly to 2.4 mg—significantly reduces the incidence of discontinuation due to gastrointestinal side effects.

Clinical trial data shows that patients receiving 2.4 mg semaglutide weekly lost an average of 15% of their baseline body weight over 68 weeks, compared to 2-3% in placebo groups. However, not every patient requires the maximum dose to achieve meaningful results; some reach plateau weight loss at 1.0 or 1.7 mg and maintain stable weight indefinitely at those levels. Your specific response determines whether advancing to 2.4 mg is necessary or optimal for your goals.

Once you reach your target maintenance dose, most treatment plans continue that same weekly injection indefinitely. Dose adjustments upward are uncommon after week 20, but downward adjustments or temporary pauses may occur if side effects emerge or weight loss plateaus. PlexusDx providers work with you to find the lowest effective dose that delivers results without unwanted effects.

Why Dose Increases Matter: Efficacy vs. Side Effects

The reason semaglutide dosing increases gradually is rooted in the balance between therapeutic benefit and tolerability. Higher doses activate GLP-1 receptors more fully, producing stronger appetite suppression, slower gastric emptying, and improved metabolic markers. However, this same receptor activation causes nausea, vomiting, and constipation in a dose-dependent manner, especially during the first weeks at each new level.

Research from the STEP clinical trial program documented that 96% of participants experienced at least one gastrointestinal side effect, but only 6% discontinued due to severity. Slow dose escalation allows your GI tract to adapt, with nausea typically resolving within 2-3 weeks at each new dose. By the time you reach 2.4 mg, your body has adjusted over months rather than experiencing a shock from a large initial dose.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

PlexusDx Compounded Semaglutide: Flexible Dosing at Flat Pricing

PlexusDx provides compounded semaglutide injections prepared by licensed 503A compounding pharmacies, available in all 50 states without insurance requirements. Pricing starts at $149 per month and remains flat regardless of which dose level you are prescribed—whether you are beginning at 0.25 mg or maintaining at 2.4 mg. This pricing structure removes the financial barrier to dose advancement and ensures you can optimize your treatment without escalating costs.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

HSA and FSA accounts are eligible for PlexusDx treatment, expanding accessibility for those with qualified high-deductible health plans. No membership fees apply, and you can adjust your commitment tier or pause therapy at any time. The goal is to provide weight loss treatment that scales with your body's needs, not your budget.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437 , FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What happens if I cannot tolerate increasing to the next semaglutide dose?

If side effects prevent advancement, your PlexusDx provider can extend the titration timeline, pause at your current dose for several extra weeks, or explore alternative GLP-1 compounds like oral semaglutide or compounded tirzepatide. Some patients achieve excellent results at 1.0 or 1.7 mg without reaching 2.4 mg, and that outcome is considered successful treatment.

How much weight can I expect to lose on semaglutide at different doses?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is PlexusDx semaglutide the same as prescription Ozempic?

PlexusDx semaglutide is compounded by licensed 503A pharmacies and contains the same active ingredient as brand-name Ozempic, but it is not FDA-approved as a finished pharmaceutical product. It delivers identical efficacy at a lower cost and with flat pricing across all dose levels—your dose may need to go up, your price won't.

How quickly does semaglutide dosing affect appetite and hunger?

Most people notice reduced appetite within 3-5 days of their first 0.25 mg injection, with effects deepening over the first two weeks. Each dose increase typically brings another wave of appetite suppression 2-3 days in, followed by GI adaptation. By week 3-4 at each dose, most patients stabilize and experience the beneficial effects without nausea.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes. PlexusDx's Precision Peptide Genetic Test identifies variants in GIPR (rs1800437) that relate to incretin signaling, plus FTO and MC4R variants affecting baseline metabolism. These insights help your provider anticipate whether you may respond robustly at lower doses or require closer monitoring during titration.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Glp 1 Dosage For Weight Loss
• Weight Loss Drugs Like Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.